Karthik Thangappan1, Awais Ashfaq1, Chet Villa2, David L S Morales1. 1. Department of Cardiothoracic Surgery, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA. 2. Department of Cardiology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
Abstract
BACKGROUND: While ventricular assist devices (VADs) remain the cornerstone of mechanical circulatory support (MCS), the total artificial heart (TAH-t) has gained popularity for certain patients in whom VAD support is not ideal. Congenital heart disease (CHD) patients often have barriers to VAD placement due to anatomic and physiological variation and thus can benefit from the TAH-t. The purpose of this study is to analyze the differences in TAH application and outcomes in patients with and without CHD. METHODS: The SynCardia Department of Clinical Research provided data upon request for all TAH-t implantations worldwide from December 1985 to October 2019. These patients were divided into two groups by pre-implantation diagnosis of CHD and non-CHD. RESULTS: A total of 1,876 patients were identified. Eighty (4%) of these patients also carried a diagnosis of CHD. There was a higher proportion of children in the CHD cohort (16.3% vs. 2.1%, P<0.001) and this translated into a lower average age amongst the two groups (34±13 vs. 49±13 years, P<0.001). There were also significantly more females in the CHD group (22.8% vs. 12.8%, P=0.010). CHD patients were more likely to be supported with a 50 cc TAH-t (11.3% vs. 4.5%, P=0.005) while all other support characteristics, including duration of support, were similar between the groups. All measured outcomes were similar between CHD and non-CHD patients including positive outcome (alive on device or transplanted), 1-month conditional survival, and rate of Freedom Driver use. CONCLUSIONS: TAH-t is an effective means to support patients with CHD. Patients with CHD had similar survival, support characteristics, and frequency of discharge compared to patients without CHD. As MCS continues to grow, its indications broadened, and its contraindications narrowed, more patient populations will see the benefit of the TAH's continuously developing technology. 2020 Annals of Cardiothoracic Surgery. All rights reserved.
BACKGROUND: While ventricular assist devices (VADs) remain the cornerstone of mechanical circulatory support (MCS), the total artificial heart (TAH-t) has gained popularity for certain patients in whom VAD support is not ideal. Congenital heart disease (CHD) patients often have barriers to VAD placement due to anatomic and physiological variation and thus can benefit from the TAH-t. The purpose of this study is to analyze the differences in TAH application and outcomes in patients with and without CHD. METHODS: The SynCardia Department of Clinical Research provided data upon request for all TAH-t implantations worldwide from December 1985 to October 2019. These patients were divided into two groups by pre-implantation diagnosis of CHD and non-CHD. RESULTS: A total of 1,876 patients were identified. Eighty (4%) of these patients also carried a diagnosis of CHD. There was a higher proportion of children in the CHD cohort (16.3% vs. 2.1%, P<0.001) and this translated into a lower average age amongst the two groups (34±13 vs. 49±13 years, P<0.001). There were also significantly more females in the CHD group (22.8% vs. 12.8%, P=0.010). CHD patients were more likely to be supported with a 50 cc TAH-t (11.3% vs. 4.5%, P=0.005) while all other support characteristics, including duration of support, were similar between the groups. All measured outcomes were similar between CHD and non-CHD patients including positive outcome (alive on device or transplanted), 1-month conditional survival, and rate of Freedom Driver use. CONCLUSIONS: TAH-t is an effective means to support patients with CHD. Patients with CHD had similar survival, support characteristics, and frequency of discharge compared to patients without CHD. As MCS continues to grow, its indications broadened, and its contraindications narrowed, more patient populations will see the benefit of the TAH's continuously developing technology. 2020 Annals of Cardiothoracic Surgery. All rights reserved.
Authors: Juliane Vierecke; Brigitta Gahl; Theo M M H de By; Herwig Antretter; Friedhelm Beyersdorf; Kadir Caliskan; Valeriya Krachak; Antonio Loforte; Evgenij Potapov; Felix Schoenrath; Bernard Stockman; Marc Vanderheyden; Bart Meyns; Jan Gummert; Paul Mohacsi Journal: Eur J Cardiothorac Surg Date: 2019-12-01 Impact factor: 4.191
Authors: David L S Morales; Muhammad S Khan; Erin A Gottlieb; Rajesh Krishnamurthy; William J Dreyer; Iki Adachi Journal: Semin Thorac Cardiovasc Surg Date: 2012
Authors: Ryan A Moore; Angela Lorts; Peace C Madueme; Michael D Taylor; David L S Morales Journal: J Heart Lung Transplant Date: 2016-01-08 Impact factor: 10.247
Authors: James K Kirklin; Rongbing Xie; Jennifer Cowger; Theo M M H de By; Takeshi Nakatani; Stephan Schueler; Rhiannon Taylor; Jenny Lannon; Paul Mohacsi; Jan Gummert; Daniel Goldstein; Kadir Caliskan; Margaret M Hannan Journal: J Heart Lung Transplant Date: 2018-01-31 Impact factor: 10.247
Authors: Farhan Zafar; Chesney Castleberry; Muhammad S Khan; Vivek Mehta; Roosevelt Bryant; Angela Lorts; Ivan Wilmot; John L Jefferies; Clifford Chin; David L S Morales Journal: J Heart Lung Transplant Date: 2014-10-14 Impact factor: 10.247
Authors: Konstantinos Dimopoulos; Gerhard-Paul Diller; Evdokia Koltsida; Antonia Pijuan-Domenech; Sofia A Papadopoulou; Sonya V Babu-Narayan; Tushar V Salukhe; Massimo F Piepoli; Philip A Poole-Wilson; Nicky Best; Darrel P Francis; Michael A Gatzoulis Journal: Circulation Date: 2008-04-28 Impact factor: 29.690
Authors: James K Kirklin; David C Naftel; Francis D Pagani; Robert L Kormos; Lynne W Stevenson; Elizabeth D Blume; Susan L Myers; Marissa A Miller; J Timothy Baldwin; James B Young Journal: J Heart Lung Transplant Date: 2015-10-08 Impact factor: 10.247
Authors: Christoph H Kiesewetter; Nick Sheron; Joseph J Vettukattill; Nigel Hacking; Brian Stedman; Harry Millward-Sadler; Marcus Haw; Richard Cope; Anthony P Salmon; Muthukumaran C Sivaprakasam; Tim Kendall; Barry R Keeton; John P Iredale; Gruschen R Veldtman Journal: Heart Date: 2006-09-27 Impact factor: 5.994
Authors: Luke J Burchill; Lina Gao; Adrienne H Kovacs; Alexander R Opotowsky; Bryan G Maxwell; Jessica Minnier; Abigail M Khan; Craig S Broberg Journal: J Am Heart Assoc Date: 2018-08-07 Impact factor: 5.501